-
1.发明授权Method for determining optimum intraocular locations for drug delivery systems 失效用于确定药物递送系统的最佳眼内位置的方法公开(公告)号：US08571802B2
公开(公告)日：2013-10-29
申请号：US11948411
申请日：2007-11-30
申请人： Michael R. Robinson , Joan-En Chang-Lin , Devin F. Welty , Scott M. Whitcup , Patrick M. Hughes
发明人： Michael R. Robinson , Joan-En Chang-Lin , Devin F. Welty , Scott M. Whitcup , Patrick M. Hughes
IPC分类号： G01N33/50
CPC分类号： A61K39/3955 , A61F9/0017 , A61K9/0048 , A61K31/573 , A61K31/58
摘要： A method for determining the optimum location for placement of an intraocular implant containing used to treat an ocular condition, particularly implants comprised of a biodegradable polymer and a therapeutic agent for the treatment of retinal tissue.
摘要翻译： 用于确定用于放置用于治疗眼部病症的眼内植入物的最佳位置的方法，特别是由可生物降解的聚合物和用于治疗视网膜组织的治疗剂组成的植入物。
-
公开(公告)号：US08524777B2
公开(公告)日：2013-09-03
申请号：US13551379
申请日：2012-07-17
IPC分类号： A61K31/14 , A61K31/557 , A61K31/5575
CPC分类号： A61K31/5575 , A61K9/0048 , A61K9/08 , A61K31/14 , A61K31/164 , A61K31/165 , A61K47/02 , A61K47/183 , A61K47/186 , A61K2300/00
摘要： A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
-
公开(公告)号：US08338479B2
公开(公告)日：2012-12-25
申请号：US12351383
申请日：2009-01-09
IPC分类号： A61K31/19 , A61K31/215
CPC分类号： A61K31/5575 , A01N33/12 , A61K9/0048 , A61K31/14 , A61K31/165 , A61K31/557 , A61K47/02 , A61K47/12
摘要： A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein.A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
-
公开(公告)号：US08299118B2
公开(公告)日：2012-10-30
申请号：US13370529
申请日：2012-02-10
IPC分类号： A61K31/19 , A61K31/215
CPC分类号： A61K31/5575 , A01N33/12 , A61K9/0048 , A61K31/14 , A61K31/165 , A61K31/557 , A61K47/02 , A61K47/12
摘要： A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
-
5.发明申请RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED MATTERS 审中-公开包含持续发布的人造植入物及相关事项公开(公告)号：US20110076318A1
公开(公告)日：2011-03-31
申请号：US12962427
申请日：2010-12-07
申请人： Patrick M. Hughes , Orest Olejnik , Glenn Tony Huang , Joan-En Chang-Lin , Thierry Nivaggioli , JaneGuo Shiah , Michele Boix , Christian Sarrazin
发明人： Patrick M. Hughes , Orest Olejnik , Glenn Tony Huang , Joan-En Chang-Lin , Thierry Nivaggioli , JaneGuo Shiah , Michele Boix , Christian Sarrazin
IPC分类号： A61M31/00 , A61K31/4436 , A61P27/02
CPC分类号： A61K31/07 , A61K9/0051 , A61K9/1647 , A61K31/203
摘要： Biocompatible intraocular implants include a retinoid component and a biodegradable polymer that is effective to facilitate release of the retinoid component into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy.
摘要翻译： 生物相容性眼内植入物包括类视黄醇组分和可生物降解的聚合物，其有效促进类视黄醇组分长时间释放到眼睛中。 植入物的治疗剂可以与可生物降解的聚合物基质相关，例如基本上不含聚乙烯醇的基质。 植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变。
-
公开(公告)号：US07851504B2
公开(公告)日：2010-12-14
申请号：US11083261
申请日：2005-03-16
IPC分类号： A61K31/19 , A61K31/215
CPC分类号： A61K31/5575 , A01N33/12 , A61K9/0048 , A61K31/14 , A61K31/165 , A61K31/557 , A61K47/02 , A61K47/12
摘要： A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein.A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
摘要翻译： 本文公开了包含0.005％至0.02％的比马前列素和100ppm至250ppm苯扎氯铵的组合物，其中所述组合物是配制用于眼部给药的水性液体。 本文还公开了可用于治疗与其有关的青光眼或高眼压症的方法。
-
7.发明申请OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR ANTERIOR COMPOUNDS HAVING ENHANCED CLEARANCE RATES 审中-公开使用具有增强清除率的ALPHA-2 ADRENERGIC受体前体化合物进行的OCALAR治疗公开(公告)号：US20080112922A1
公开(公告)日：2008-05-15
申请号：US11949750
申请日：2007-12-03
申请人： Patrick HUGHES , James Burke , Joan-En Chang-Lin
发明人： Patrick HUGHES , James Burke , Joan-En Chang-Lin
IPC分类号： A61K31/765
CPC分类号： A61K9/0051 , A61K9/0048 , A61K9/1647
摘要： Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.
摘要翻译： 眼科治疗材料，例如含液组合物和聚合物药物递送系统，包括治疗成分，其包括α2肾上腺素能受体激动剂，其从施用该物质的个体眼睛的前段清除。 α2肾上腺素能受体激动剂可具有大于约3小时的玻璃体半衰期。 本发明的材料可有效治疗影响眼前段或眼部前段和后段的眼睛状况。 这些材料适用于玻璃体内或眼周内给药，并且可以为已经施用材料的患者提供延长的药物递送和治疗益处。 α2肾上腺素能受体激动剂可以在含液制剂和/或生物可侵蚀和/或非生物可侵蚀的聚合物植入物和微粒中提供。 还描述了制备和使用本发明材料的方法。
-
8.发明申请公开(公告)号：US20070066541A1
公开(公告)日：2007-03-22
申请号：US11521872
申请日：2006-09-15
申请人： Patrick Hughes , Orest Olejnik , Joan-En Chang-Lin
发明人： Patrick Hughes , Orest Olejnik , Joan-En Chang-Lin
IPC分类号： A61K38/04 , A61K31/513 , A61K31/498 , A61K31/557
CPC分类号： A61K31/557 , A61K9/0048 , A61K31/498 , A61K31/513 , A61K47/542 , A61K47/549 , A61K47/55 , A61K47/551 , A61K47/64
摘要： Membrane transporter-targeted therapeutic agents and methods of making and using the same.
摘要翻译： 膜转运体靶向治疗剂及其制备和使用方法。
-
公开(公告)号：US20060258617A1
公开(公告)日：2006-11-16
申请号：US11460392
申请日：2006-07-27
申请人： Robert Lyon , Chin-Ming Chang , Joan-En Chang-Lin , James Chang , Orest Olejnik
发明人： Robert Lyon , Chin-Ming Chang , Joan-En Chang-Lin , James Chang , Orest Olejnik
IPC分类号： A61K31/724 , A61K31/717 , A61K31/573
CPC分类号： A61K9/0014 , A61K9/0048 , A61K31/57 , A61K31/573 , A61K31/724 , A61K47/38 , A61K47/40
摘要： Disclosed herein are methods of delivering drugs or therapeutically active agents to the back of the eye via topical administration of compositions comprising cyclodextrin derivatives. Compositions related thereto are also disclosed herein.
摘要翻译： 本文公开了通过局部施用包含环糊精衍生物的组合物将药物或治疗活性剂递送至眼睛后部的方法。 本文还公开了与其相关的组合物。
-
公开(公告)号：US20060106104A1
公开(公告)日：2006-05-18
申请号：US10990811
申请日：2004-11-16
申请人： Joseph Vehige , Peter Simmons , Joan-En Chang-Lin
发明人： Joseph Vehige , Peter Simmons , Joan-En Chang-Lin
IPC分类号： A61K31/22 , A61K31/185 , A61K31/205 , A61K31/045
CPC分类号： A61K31/205 , A61K9/0048 , A61K9/08 , A61K31/047 , A61K31/14 , A61K31/70 , A61K31/717 , A61K31/728 , A61K38/1732 , A61K47/02 , A61K47/26 , A61K47/38
摘要： Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
-
-
-
-
-
-
-
-
-
搜索结果
42 条记录 (耗时 0.032 秒)
